NCT04873570

Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects

A Single Center, Open Label, Randomized, Single-dose, Two-period, Two-way Cross-over Study to Compare the Rate and Extent of Absorption of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: University of Karachi · Academic / Other
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Single oral dose, of test and reference Tablet will be administered to healthy volunteers, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-points. Blood samples will be taken up to 72.0 hours post-dose.

Conditions

• Healthy Individuals
• Bioequivalence Study

Interventions

Type	Name	Description
DRUG	Moxifloxacin 400mg	Moxifloxacin 400mg IR tablet

Timeline

• Start date: 2021-05-28
• Primary completion: 2021-06-08
• Completion: 2021-06-10
• First posted: 2021-05-05
• Last updated: 2022-09-07

Locations

1 site across 1 country: Pakistan